Literature DB >> 22910411

DP97, a DEAD box DNA/RNA helicase, is a target gene-selective co-regulator of the constitutive androstane receptor.

Yuichiro Kanno1, Takafumi Serikawa, Jun Inajima, Yoshio Inouye.   

Abstract

The constitutive androstane receptor (CAR) plays a key role in the expression of xenobiotic/steroid and drug metabolizing enzymes and their transporters. In this study, we demonstrated that DP97, a member of the DEAD box DNA/RNA helicase protein family, is a novel CAR-interacting protein. Using HepG2 cells expressing human CAR in the presence of tetracycline, we showed that knockdown of DP97 with small interfering RNAs suppressed tetracycline-inducible mRNA expression of CYP2B6 and UGT1A1 but not CYP3A4. Thus, DP97 was found to be a gene (or promoter)-selective co-activator for hCAR. DP97-mediated CAR transactivation was synergistically enhanced by the co-expression of SRC-1 or PGC1α, therefore it might act as mediator between hCAR and appropriate co-activators.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22910411     DOI: 10.1016/j.bbrc.2012.08.027

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Nigramide J is a novel potent inverse agonist of the human constitutive androstane receptor.

Authors:  Yuichiro Kanno; Nobuaki Tanuma; Tomofumi Yatsu; Wei Li; Kazuo Koike; Yoshio Inouye
Journal:  Pharmacol Res Perspect       Date:  2014-01-26

2.  DDX54 regulates transcriptome dynamics during DNA damage response.

Authors:  Miha Milek; Koshi Imami; Neelanjan Mukherjee; Francesca De Bortoli; Ulrike Zinnall; Orsalia Hazapis; Christian Trahan; Marlene Oeffinger; Florian Heyd; Uwe Ohler; Matthias Selbach; Markus Landthaler
Journal:  Genome Res       Date:  2017-06-08       Impact factor: 9.043

3.  DDX54 Plays a Cancerous Role Through Activating P65 and AKT Signaling Pathway in Colorectal Cancer.

Authors:  Yi Yu; Jing-Long Wang; Li-Li Meng; Chun-Ting Hu; Zhao-Wen Yan; Zhi-Ping He; Xiao-Qin Shi; Guo-Hui Fu; Li-Dong Zu
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.